Form 4: Avidity Biosciences CFO MacLean Reports Stock Transactions Following PSU Vesting

Avidity Biosciences' CFO, Michael MacLean, reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

Summary

• On September 19, 2024, Avidity Biosciences CFO Michael MacLean acquired 25,000 shares of common stock due to the vesting of performance-based restricted stock units (PSUs) at a price of $0.
• These PSUs vested upon the achievement of a clinical event related to del-brax.
• To cover tax withholding obligations related to the PSU vesting, MacLean sold 11,510 shares of common stock on September 23, 2024, at a weighted-average price of $44.
• Following these transactions, MacLean directly owns 96,355 shares of Avidity Biosciences common stock.
• An additional 25,000 PSUs were earned and converted to time-based restricted stock units vesting on March 19, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports routine transactions related to executive compensation and tax obligations. The vesting of PSUs is a positive signal, but the subsequent sale is a standard procedure.

Positives

• The vesting of PSUs indicates the achievement of a company performance objective (clinical event related to del-brax).

Future Outlook

An additional 25,000 PSUs were earned and converted to time-based restricted stock units that will vest in full on March 19, 2025, subject to continued employment.

Industry Context

Tracking insider transactions provides insights into management's confidence and can be a signal for investors, especially in the biotech industry where clinical milestones are critical.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies to manage tax obligations related to equity compensation.
• The vesting of PSUs tied to clinical milestones is a typical incentive structure in the biotechnology industry, aligning management's interests with the company's success in drug development.

Stakeholder Impact

• Shareholders may view the PSU vesting as a positive sign of the company achieving its clinical milestones.
• The sell-to-cover transaction has a minor dilutive effect on existing shareholders.

Key Dates